BARD1 LIFE SCIENCES LIMITED
ASX:BD1
Last Placement
Not Available
Not Available
$3.3M
$0.0320
Not Available
Nov 8, 2018
Company Information
BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes two development-stage BARD1 autoantibody tests for early detection of lung and ovarian cancers, and a research-stage cancer vaccine under evaluation for treatment of cancer. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.
Type
Listed Company
GICS Sub-Industry
Health Care Services
Head Office
431 Roberts Rd, Subiaco WA 6008, Australia
Website
Quarterly Cash Flows
The numbers below are derived from quarterly cash flow reports provided by the company. Fresh Equities does not guarantee that the information provided is accurate, you can read the associated report by clicking read more for the quarter. Always do your own research and do not rely on the information provided here as your only source of research.